Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-10-17FDA Approved: GAZYVA — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for GAZYVA (obinutuzumab) from Genentech to expand its approved indications.
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 2]
Phase 2 clinical trial update assessing changes in disease activity and adverse events when oral venetoclax is combined with intravenous obi…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients [Phase 1]
Phase 1 study assessing rituximab plus high-dose methylprednisolone debulking before venetoclax in patients with chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) [Phase 2]
A Phase 2 clinical trial evaluating the combination of venetoclax and obinutuzumab in chronic lymphocytic leukemia is ongoing, with the stud…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Family Study of Lymphoproliferative Disorders
A Mayo Clinic-led clinical trial is a family study investigating lymphoproliferative disorders, currently in the recruitment phase.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 2]
A Phase II randomized trial evaluating a Bruton tyrosine kinase inhibitor with or without venetoclax in veterans with chronic lymphocytic le…
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL [Phase 1]
Phase 1 trial of JBH492 as monotherapy in chronic lymphocytic leukemia and non-Hodgkin lymphoma reports safety and preliminary efficacy; the…
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies [Phase 1]
Phase 1 study of odronextamab in CD20+ B-cell malignancies completed; the trial reported safety and tolerability data in diseases including …
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) [Phase 1]
This clinical trial update reports the Phase 1 study of JNJ-75348780 in participants with Non-Hodgkin lymphoma and chronic lymphocytic leuke…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Q702 for the Treatment of Patients With Hematologic Malignancies [Phase 1]
This entry notes a Phase 1 clinical trial (Q702) for hematologic malignancies led by Mayo Clinic, currently recruiting and including histioc…
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies [Phase 1]
Phase 1 clinical trial update of acalabrutinib in Japanese adults with advanced B-cell malignancies, including relapsed/refractory CLL and m…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation [Phase 2]
Phase 2 clinical trial evaluating polatuzumab vedotin in combination with chemotherapy for Richter syndrome and chronic lymphocytic leukemia…
-
EMA approval · 2025-10-06EMA Authorised: Rixathon (rituximab) — Sandoz GmbH
EMA authorised Rixathon (rituximab) by Sandoz as a biosimilar to Rituxan for several autoimmune and hematologic diseases, expanding access t…
-
CLINICAL_TRIALS trial_result · 2025-10-06Clinical Trial Update: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating cellular immunotherapy after chemotherapy in patients with recurrent B-cell lymphoid cancers, including Non-Hodgkin…
-
CLINICAL_TRIALS other · 2025-10-06Clinical Trial Update: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of loncastuximab tesirine and mosunetuzumab for relapsed or refractory diffuse large …
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) [Phase 3]
A Phase III study (PRO-SID) evaluating Panzyga for primary infection prophylaxis in patients with chronic lymphocytic leukemia and hypogamma…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial [Phase 3]
Adaptive Phase 3 trial assessing optimized COVID-19 vaccination schedules for immunocompromised individuals, including patients with HIV and…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) [Phase 1]
Sana Biotechnology's investigational candidate SC291 is being studied in a Phase 1 ARDENT trial for relapsed/refractory B-cell malignancies,…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial update notes the addition of Loncastuximab tesirine to acalabrutinib for chronic lymphocytic leukemia; the study is active but…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy
A registry study tracking immune-related adverse events in cancer patients receiving immunotherapy. The study is not yet recruiting and is s…
-
EMA approval · 2025-09-29EMA Authorised: Blitzima (rituximab) — Celltrion Healthcare Hungary Kft.
EMA authorized Blitzima (rituximab) from Celltrion Healthcare Hungary Kft. for non-Hodgkin lymphoma and chronic lymphocytic leukemia.
-
EMA approval · 2025-09-29EMA Authorised: Truxima (rituximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Truxima (rituximab) by Celltrion Healthcare Hungary Kft. as a biosimilar rituximab for several indications including Non-Hodg…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL [Phase 1, Phase 2]
A Phase Ib study of the selective PKC-β inhibitor MS-553 in patients with refractory or relapsed chronic lymphocytic leukemia or small lymph…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Financial Difficulty in Patients With Blood Cancer
This clinical trial update notes the completion of a study evaluating financial difficulties experienced by patients with blood cancers, spe…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies [Phase 1, Phase 2]
An ongoing Phase 1/2 clinical trial of GNC-035 for relapsed/refractory chronic lymphocytic leukemia (and other hematological malignancies) i…